AMRI merges discovery chemistry and biology functions
Creates global drug discovery organisation
Albany Molecular Research Inc (AMRI) is to merge its discovery r&d and discovery chemistry departments to form a global drug discovery organisation. Bruce Sargent, newly appointed as senior vice president, drug discovery, will head the expanded organisation.
Under this reorganisation, the US supplier of pharmaceutical services will combine its discovery chemistry and biology functions into a single unit across locations worldwide.
AMRI says customers will benefit from its experience in performing fully coordinated multidisciplinary discovery projects using a global network of scientific experts, laboratories and equipment in medicinal chemistry, biology and/or ADMET.
‘Customers are increasingly seeking out CROs that can provide them with fully integrated solutions in their pursuit to diminish costs and project timelines, while still desiring to maintain a high level of quality and value,’ said AMRI chairman, ceo and president Thomas D'Ambra.
‘We believe that combining all of our discovery capabilities in biology and discovery chemistry under the direction of Dr Sargent will further enhance AMRI's ability to generate significant value for our customers and stakeholders.’